176 related articles for article (PubMed ID: 16850271)
1. Topical iontophoresis of valaciclovir hydrochloride improves cutaneous aciclovir delivery.
Abla N; Naik A; Guy RH; Kalia YN
Pharm Res; 2006 Aug; 23(8):1842-9. PubMed ID: 16850271
[TBL] [Abstract][Full Text] [Related]
2. Topical iontophoretic delivery of ionizable, biolabile aciclovir prodrugs: A rational approach to improve cutaneous bioavailability.
Chen Y; Alberti I; Kalia YN
Eur J Pharm Biopharm; 2016 Feb; 99():103-13. PubMed ID: 26686649
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous biodistribution of ionizable, biolabile aciclovir prodrugs after short duration topical iontophoresis: Targeted intraepidermal drug delivery.
Chen Y; Zahui T; Alberti I; Kalia YN
Eur J Pharm Biopharm; 2016 Feb; 99():94-102. PubMed ID: 26592154
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of valacyclovir in the adult horse.
Maxwell LK; Bentz BG; Bourne DW; Erkert RS
J Vet Pharmacol Ther; 2008 Aug; 31(4):312-20. PubMed ID: 18638291
[TBL] [Abstract][Full Text] [Related]
5. Short-duration ocular iontophoresis of ionizable aciclovir prodrugs: A new approach to treat herpes simplex infections in the anterior and posterior segments of the eye.
Chen Y; Kalia YN
Int J Pharm; 2018 Jan; 536(1):292-300. PubMed ID: 29198810
[TBL] [Abstract][Full Text] [Related]
6. In vivo quantification of acyclovir exposure in the dermis following iontophoresis of semisolid formulations.
Shukla C; Friden P; Juluru R; Stagni G
J Pharm Sci; 2009 Mar; 98(3):917-25. PubMed ID: 18623192
[TBL] [Abstract][Full Text] [Related]
7. The influence of iontophoresis on acyclovir transport and accumulation in rabbit ear skin.
Padula C; Sartori F; Marra F; Santi P
Pharm Res; 2005 Sep; 22(9):1519-24. PubMed ID: 16132364
[TBL] [Abstract][Full Text] [Related]
8. Topical delivery of different acyclovir palmitate liposome formulations through rat skin in vitro.
Liu H; Pan WS; Tang R; Luo SD
Pharmazie; 2004 Mar; 59(3):203-6. PubMed ID: 15074594
[TBL] [Abstract][Full Text] [Related]
9. Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment.
Hasenburg A; Tong XW; Rojas-Martinez A; Nyberg-Hoffman C; Kieback CC; Kaplan AL; Kaufman RH; Ramzy I; Aguilar-Cordova E; Kieback DG
Anticancer Res; 1999; 19(3B):2163-5. PubMed ID: 10472325
[TBL] [Abstract][Full Text] [Related]
10. Topical application of acyclovir-loaded microparticles: quantification of the drug in porcine skin layers.
de Jalón EG; Blanco-Príeto MJ; Ygartua P; Santoyo S
J Control Release; 2001 Jul; 75(1-2):191-7. PubMed ID: 11451509
[TBL] [Abstract][Full Text] [Related]
11. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea.
Anand B; Nashed Y; Mitra A
Curr Eye Res; 2003; 26(3-4):151-63. PubMed ID: 12815543
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.
Steingrimsdottir H; Gruber A; Palm C; Grimfors G; Kalin M; Eksborg S
Antimicrob Agents Chemother; 2000 Jan; 44(1):207-9. PubMed ID: 10602752
[TBL] [Abstract][Full Text] [Related]
13. In vivo ocular pharmacokinetics of acyclovir dipeptide ester prodrugs by microdialysis in rabbits.
Anand BS; Katragadda S; Gunda S; Mitra AK
Mol Pharm; 2006; 3(4):431-40. PubMed ID: 16889437
[TBL] [Abstract][Full Text] [Related]
14. Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits.
Chetoni P; Rossi S; Burgalassi S; Monti D; Mariotti S; Saettone MF
J Ocul Pharmacol Ther; 2004 Apr; 20(2):169-77. PubMed ID: 15117573
[TBL] [Abstract][Full Text] [Related]
15. Acyclovir skin depot characterization following in vivo iontophoretic delivery.
Siddoju S; Sachdeva V; Friden PM; Yu YY; Banga AK
Skin Res Technol; 2011 May; 17(2):234-44. PubMed ID: 21272079
[TBL] [Abstract][Full Text] [Related]
16. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.
Katragadda S; Gunda S; Hariharan S; Mitra AK
Int J Pharm; 2008 Jul; 359(1-2):15-24. PubMed ID: 18472234
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of acyclovir cream and gel formulations for transdermal iontophoretic delivery.
Siddoju S; Sachdeva V; Friden PM; Banga AK
Ther Deliv; 2012 Mar; 3(3):327-38. PubMed ID: 22833993
[TBL] [Abstract][Full Text] [Related]
18. Estimation of skin target site acyclovir concentrations following controlled (trans)dermal drug delivery in topical and systemic treatment of cutaneous HSV-1 infections in hairless mice.
Imanidis G; Song WQ; Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1994 Jul; 11(7):1035-41. PubMed ID: 7937545
[TBL] [Abstract][Full Text] [Related]
19. Synergistic penetration of ethosomes and lipophilic prodrug on the transdermal delivery of acyclovir.
Zhou Y; Wei YH; Zhang GQ; Wu XA
Arch Pharm Res; 2010 Apr; 33(4):567-74. PubMed ID: 20422366
[TBL] [Abstract][Full Text] [Related]
20. Assessment of correlation between skin target site free drug concentration and the in vivo topical antiviral efficacy in hairless mice for (E)-5-(2-bromovinyl)-2'-deoxyuridine and acyclovir formulations.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; De Clercq E; El-Shattawy HH
J Pharm Sci; 1998 Aug; 87(8):917-21. PubMed ID: 9687333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
